Archive · 31 Jul 2025
Celiac Drug Shows Promise in Treating Post-Covid Syndrome
Some children who get Covid-19 also get a very serious illness called MIS-C.
Doctors have been trying to find ways to help these children feel better.
A drug that helps people with a gut problem called coeliac disease seems to work.
In a small study, kids with MIS-C were given either the drug or a pretend medicine.
The kids who got the drug felt better faster and could do their normal activities quicker.
Now, scientists are testing if this drug could help people with long Covid.
A drug for celiac disease, larazotide, showed promise in treating severe post-Covid syndrome in children.
The study focused on children with multisystem inflammatory syndrome in children (MIS-C), a severe condition following Covid-19 infection.
Larazotide was administered orally in a double-blind clinical trial.
Children who received larazotide showed faster resolution of gastrointestinal symptoms and quicker return to normal activities.
Researchers are testing whether larazotide may be useful for long Covid.
- Who
- Researchers tested larazotide on children experiencing early-stage MIS-C.
- What
- A drug designed for celiac disease showed promise in treating severe post-Covid syndrome in children.
- When
- Trial results were recently published.
- Where
- The study was conducted at Mass General Brigham.
- Why
- To test larazotide's efficacy and safety as an MIS-C treatment.
- Drug
- Larazotide
- Target Condition
- Severe post-Covid syndrome (MIS-C)
- Study Type
- Double-blind clinical trial
- Participants
- 12 children
- Treatment Duration
- 21 days
- Administration
- Oral
- Key Outcomes
- Faster recovery of gastrointestinal symptoms and quicker return to normal activities
